Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative ResearchBusiness Wire • 03/16/26
Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?Zacks Investment Research • 03/09/26
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer TherapiesThe Motley Fool • 03/05/26
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ETGlobeNewsWire • 03/04/26
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You'd Expect24/7 Wall Street • 03/03/26
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)Business Wire • 02/28/26
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)Business Wire • 02/28/26
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian CancerBusiness Wire • 02/27/26
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After SurgeryBusiness Wire • 02/27/26
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung CancerBusiness Wire • 02/26/26
Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVieSeeking Alpha • 02/26/26